Zacks Research Upgrades Alterity Therapeutics to Hold Rating

Alterity Therapeutics (NASDAQ: ATHE) received a new rating from Zacks Research, which has upgraded the company’s stock to a “hold” status. This decision was made public in a report issued on Thursday, focusing on the ongoing developments surrounding the clinical-stage biotechnology firm.

Several other analysts have also provided insights into Alterity Therapeutics in recent weeks. Notably, Weiss Ratings reaffirmed a “sell (e+)” rating for the company on January 21, while Canaccord Genuity Group initiated coverage with a “speculative buy” recommendation on December 17. Currently, one analyst rates the stock as a Buy, another as a Hold, and a third has assigned a Sell rating. According to data from MarketBeat, the consensus rating for Alterity Therapeutics remains at “Hold.”

Institutional Investment Activity

In addition to the rating changes, several institutional investors have adjusted their positions in Alterity Therapeutics. HB Wealth Management LLC made a significant move by acquiring a new stake valued at approximately $220,000 during the third quarter. Meanwhile, Twin Lakes Capital Management LLC raised its stake by a remarkable 2,250.3%, bringing its total ownership to 139,258 shares worth about $524,000 after purchasing an additional 133,333 shares.

Citadel Advisors LLC also entered the picture by acquiring a new stake valued at $83,000. Furthermore, Greenleaf Trust increased its holdings by 88.2%, now owning 32,000 shares valued at $120,000 after acquiring an additional 15,000 shares. Currently, hedge funds and other institutional investors hold approximately 2.14% of Alterity’s stock.

About Alterity Therapeutics

Alterity Therapeutics is dedicated to developing innovative treatments for neurological and neurodegenerative disorders. The company’s research focuses on small molecules aimed at addressing the underlying mechanisms of diseases, particularly those related to enhancing synaptic function and reducing neuroinflammation.

Among its most notable assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1. This candidate is currently undergoing clinical trials for the treatment of Rett syndrome and Fragile X syndrome, marking a significant step in addressing these challenging conditions.

As the landscape for biotechnology continues to evolve, Alterity Therapeutics remains a company to watch, especially with the recent adjustments in ratings and institutional investments reflecting growing interest in its future potential.